Reducing Salivary Toxicity with Adaptive Radiotherapy (ReSTART): A Randomized Controlled Trial Comparing Conventional...

Area of Science:

• Radiation Oncology
• Head and Neck Cancer Treatment
• Clinical Trials

Background:

• Adaptive Radiotherapy (ART) shows promise in reducing xerostomia for Head and Neck Squamous Cell Carcinoma (HNSCC).
• Limited randomized evidence exists for ART's efficacy in HNSCC treatment.
• Previous studies suggest ART can decrease parotid gland radiation doses.

Purpose of the Study:

• To evaluate the efficacy of Adaptive Radiotherapy (ART) in reducing salivary toxicity compared to standard Intensity Modulated Radiotherapy (IMRT).
• To assess the primary endpoint of salivary toxicity using salivary scintigraphy at 12 months post-radiation.
• To compare secondary endpoints including acute and late toxicities, survival rates, and quality of life.

Main Methods:

• The ReSTART trial is a phase III randomized study for locally advanced HNSCC.
• Patients receive either standard IMRT (5 mm Planning Target Volume margin) or ART (3 mm PTV margin with adaptive planning).
• The primary endpoint is salivary toxicity assessed by scintigraphy at 12 months; 130 patients are required.

Main Results:

• This section is not applicable as the study is ongoing and results are not yet available.

Conclusions:

• The ReSTART trial addresses a critical question regarding ART in HNSCC, especially in resource-limited settings.
• Unique aspects include reduced PTV margins in the ART arm and scintigraphy-based xerostomia assessment.
• The trial aims to provide robust randomized evidence for ART's benefit in HNSCC patients.